4 Top-Performing Liquid Stocks to Enhance Portfolio Returns
Source: Nasdaq

Zacks screened for liquid, asset-efficient companies with current, quick and cash ratios between 1 and 3, above-industry asset utilization, a Zacks Rank #1 and Growth Score of A or B, identifying eight qualifying stocks including ANF, EVER, SEZL and ANGI. Abercrombie raised fiscal 2024 sales-growth guidance to 12-13%, while Sezzle raised its 2024 revenue-growth outlook to 35-40% and EPS outlook to $9.25 from $5.00 after quarterly revenue rose 60% year over year. EverQuote and Angi also showed strong historical earnings-surprise metrics, though the article is primarily a stock-screening recommendation rather than a material market-moving event.
Analysis
The screen itself is not a catalyst: liquidity and asset-turnover factors are backward-looking and the promotional framing makes the signal low-conviction. The investable distinction is whether excess cash supports durable reinvestment and buybacks versus masks a cyclical peak in earnings. ANF and SEZL have the greatest multiple risk because their earnings trajectories already embed unusually strong execution; EVER has a cleaner operating-leverage setup if carrier marketing budgets normalize further, while ANGI remains a turnaround rather than a liquidity story.
Over the next 1-3 months, ANF’s key sensitivity is fourth-quarter markdown intensity and holiday traffic rather than reported sales growth. A modest deterioration in gross margin can outweigh the benefit of elevated inventory turns, and apparel peers such as AEO and URBN provide better real-time read-throughs on promotional pressure. For SEZL, the relevant liquidity test is credit performance through holiday cohorts: higher transaction volume is only valuable if net transaction loss and funding costs remain contained; AFRM is the most useful public comp and potential hedge.
EVER’s revenue model has asymmetric upside if auto insurers increase customer-acquisition spend as rate adequacy improves, but this is a concentrated-budget, small-cap outcome rather than a broad insurtech recovery. ANGI’s improving unit monetization could lift EBITDA disproportionately if fixed sales-and-marketing costs stay controlled, yet housing turnover and homeowner discretionary repair demand remain binding constraints. Consensus may be over-crediting the quality of a one-factor screen and under-crediting that the names have materially different exposure to consumer credit, insurance ad budgets, and discretionary retail demand.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
Key Decisions for Investors
- No basket trade on the liquidity screen; treat it as an alert only. Require next-quarter cash conversion, working-capital movement, and guidance revisions before deploying capital.
- Prefer a 3-6 month long EVER position versus short GOOGL or a diversified digital-ad proxy only after evidence that auto-carrier acquisition budgets are rising; target 2:1 upside/downside. Exit if revenue-per-quote-request or carrier spend commentary weakens.
- For ANF, avoid chasing strength into holiday results; consider a 1-3 month tactical short or long put spread if AEO/URBN report rising promotions or ANF signals gross-margin pressure. Thesis is falsified by sustained full-price sell-through and an upward operating-margin guide.
- Use SEZL only as a high-volatility event trade around earnings, preferably long stock paired with short AFRM to isolate subscription/merchant-execution upside from BNPL beta. Cut if delinquency or net-loss metrics rise materially, or if funding costs outpace take-rate expansion.
- Keep ANGI on a watchlist rather than initiate: revisit long exposure if service-professional monetization continues to rise while adjusted EBITDA and free cash flow inflect positive for two consecutive quarters; downside remains tied to housing-related demand softness.
More News
- What next for France as riots rattle markets? Three questions facing investors ahead of more protests
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What Is an AI Investment Research Platform?
- What Exactly Does Post-Training in LLMs and Finance-Focused AI Actually Mean for Asset Managers?